As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them

Around the world, patients suddenly can’t find enough of the insulins made by companies they have long relied on to do so.

In the U.S., Novo Nordisk’s recent decision to discontinue a product has left patients with fewer options. At the same time, patients are encountering shortages of other products from Novo and Eli Lilly